El-Khoueiry, A BA BEl-KhoueiryTrojan, JJTrojanMeyer, TTMeyerYau, TTYauMelero, IIMeleroKudo, MMKudoCHIUN HSUKim, T-YT-YKimChoo, S-PS-PChooKang, Y-KY-KKangYeo, WWYeoChopra, AAChopraSoleymani, SSSoleymaniYao, JJYaoNeely, JJNeelyTschaika, MMTschaikaWelling, T HT HWellingSangro, BBSangro2024-03-282024-03-282024-01-2509237534https://scholars.lib.ntu.edu.tw/handle/123456789/641520Patients with advanced hepatocellular carcinoma (aHCC) have a poor prognosis and high mortality. Nivolumab monotherapy demonstrated clinical benefit with an acceptable safety profile in patients with aHCC in the CheckMate 040 study. Five-year follow-up of the sorafenib-naive and sorafenib-experienced groups of CheckMate 040 is presented here.enadvanced hepatocellular carcinoma; checkpoint inhibitor; nivolumab; sorafenib[SDGs]SDG3journal article10.1016/j.annonc.2023.12.008381511842-s2.0-85183958010https://api.elsevier.com/content/abstract/scopus_id/85183958010